The Genedrive HCV ID Kit is a qualitative HCV assay providing results within 90 minutes in a decentralised testing environment. Credit: Genedrive.

Molecular diagnostics company Genedrive premiered its Genedrive hepatitis C virus (HCV) ID kit at the MEDLAB Asia Pacific Exhibition & Congress in Singapore.

The qualitative HCV assay is marketed as ‘an accurate and cost-effective molecular solution for HCV testing’. It provides results within 90 minutes and does not require viral RNA extraction as it only requires a patient’s plasma.  The assay is a potential solution for low-throughput, decentralised laboratories and is designed for use in this environment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genedrive chief executive David Budd said: “The Genedrive HCV ID Kit is being presented to key opinion leaders and distribution partners at company’s booth M19.

“With the advent of new curative direct acting antiviral treatments for HCV, we believe that there is a major opportunity to support tackling the global burden of the disease if accurate, decentralised diagnostics can be used to identify those living with HCV and give them access to therapy.”

The test kit has been created to support the increasing number of direct-acting antiviral treatments in low and middle income countries.

Traditional diagnostic tests for HCV are complex and this means they are often only used in specialised hospital laboratories. Modern direct acting antiviral agents have led to the diagnostic algorithm being simplified and treatment can now be administered immediately following the positive detection of HCV RNA.

Decentralised molecular diagnostics could make HCV testing widely available and provide rapid identification of patients that could benefit from these treatments.

The Genedrive HCV ID test is performed on the company’s portable molecular diagnostics platform.

Over 4,000 medical technology delegates from around the world are attending MEDLAB to showcase and explore their technologies and innovations in the field of laboratory diagnostics. The congress showcases products in many areas including point of need and infectious diseases.